BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B. 2006;7:627-633. [PMID: 16845716 DOI: 10.1631/jzus.2006.b0627] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Azeemuddin M, Rafiq M, Anturlikar SD, Sharath Kumar LM, Patki PS, Babu UV, Shyam R. Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis. J Tradit Complement Med 2016;6:160-7. [PMID: 27114939 DOI: 10.1016/j.jtcme.2014.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Tzanetakou IP, Doulamis IP, Korou LM, Agrogiannis G, Vlachos IS, Pantopoulou A, Mikhailidis DP, Patsouris E, Vlachos I, Perrea DN. Water Soluble Vitamin E Administration in Wistar Rats with Non-alcoholic Fatty Liver Disease. Open Cardiovasc Med J. 2012;6:88-97. [PMID: 22930662 DOI: 10.2174/1874192401206010088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Deenin W, Malakul W, Boonsong T, Phoungpetchara I, Tunsophon S. Papaya improves non-alcoholic fatty liver disease in obese rats by attenuating oxidative stress, inflammation and lipogenic gene expression. World J Hepatol 2021;13:315-27. [PMID: 33815675 DOI: 10.4254/wjh.v13.i3.315] [Reference Citation Analysis]
4 Zaitone SA, Barakat BM, Bilasy SE, Fawzy MS, Abdelaziz EZ, Farag NE. Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure. Naunyn Schmiedebergs Arch Pharmacol. 2015;388:587-600. [PMID: 25708949 DOI: 10.1007/s00210-015-1102-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
5 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:18070-91. [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 174] [Cited by in F6Publishing: 145] [Article Influence: 29.0] [Reference Citation Analysis]
6 Wang HN, Wang YR, Liu GQ, Liu Z, Wu PX, Wei XL, Hong TP. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol. 2008;14:7240-7246. [PMID: 19084941 DOI: 10.3748/wjg.14.7240] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
7 Al-Muzafar HM, Amin KA. Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin. Exp Ther Med 2018;16:2938-48. [PMID: 30214514 DOI: 10.3892/etm.2018.6563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Li D, Zheng J, Hu Y, Hou H, Hao S, Liu N, Wang Y. Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats. Pharmacogn Mag 2017;13:677-82. [PMID: 29200733 DOI: 10.4103/pm.pm_584_16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
9 Zhang W, An R, Li Q, Sun L, Lai X, Chen R, Li D, Sun S. Theaflavin TF3 Relieves Hepatocyte Lipid Deposition through Activating an AMPK Signaling Pathway by targeting Plasma Kallikrein. J Agric Food Chem 2020;68:2673-83. [DOI: 10.1021/acs.jafc.0c00148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
10 Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, Saghir SAM, Usman NS, Al-Dulaimi DW, Yam MF. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients. 2017;9:776. [PMID: 28718838 DOI: 10.3390/nu9070766] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]